Clinical Edge Journal Scan

Laparoscopic anatomic hepatectomy achieves better follow-up outcomes than non-anatomical hepatectomy in HCC


 

Key clinical point: As laparoscopic anatomical hepatectomy (LAH) is associated with increased disease-free survival (DFS) and comparable long-term overall survival (OS) and postoperative complications compared with non-anatomical hepatectomy (LNAH), it is recommended over LNAH for selected patients with HCC.

Major finding: Patients who underwent LAH vs LNAH showed significantly higher 5-year DFS rate (33.9% vs 30.1%; P = .009) and comparable long-term OS (43.2% vs 35.2%; P = .054) and postoperative complication (8.9% vs 12.4%; P = .255) rates.

Study details: Findings are from a single-center, prospective randomized controlled trial including 385 adult patients with HCC (single tumor ≤10 cm in size) who were randomly assigned to undergo LAH (n = 192) or LNAH (n = 193).

Disclosures: The study was sponsored by the National Natural Science Foundation of China and Project of Chongqing Municipality. The authors reported no conflicts of interest.

Source: Liao K et al. Laparoscopic anatomical versus non-anatomical hepatectomy in the treatment of hepatocellular carcinoma: A randomised controlled trial. Int J Surg. 2022;102:106652 (May 4). Doi: 10.1016/j.ijsu.2022.106652

Recommended Reading

Tenofovir vs. entecavir: Better therapeutic in HBV-related HCC after radiofrequency ablation
Federal Practitioner
TACE is safe and effective in elderly patients with intermediate HCC
Federal Practitioner
TACE vs. LR: Better prognosis in HCC with bile duct tumor thrombus?
Federal Practitioner
Post-LT HCC recurrence unaffected by donor sex
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC May 2022
Federal Practitioner
Psychosocial Barriers and Their Impact on Hepatocellular Carcinoma Care in US Veterans: Tumor Board Model of Care
Federal Practitioner
Early-stage HCC: OLT offers better survival outcomes than ablative therapies in the elderly
Federal Practitioner
Pembrolizumab monotherapy shows promise for untreated advanced HCC in phase 2
Federal Practitioner
Subsequent anticancer therapy after ICI treatment prolongs survival in HCC
Federal Practitioner
Does imaging surveillance intensity govern clinical outcomes in HCC?
Federal Practitioner